The Clinical Trial Pipeline: Inside Eximia Research, Private Equity Site Networks, and Burbank’s Medical Testing Economy

Executive Summary: The Hidden Bio-Pharmaceutical Economy

Every day, hundreds of Burbank residents walk into nondescript commercial office buildings across the Media District, the Magnolia Park corridor, and the San Fernando industrial strip to participate in clinical trials. They are not visiting their primary care doctors or seeking hospital emergency care. Instead, they are volunteering their blood, lungs, central nervous systems, and daily health metrics to test investigational new drugs (INDs) for multinational pharmaceutical sponsors such as Pfizer, Eli Lilly, AbbVie, Novartis, and AstraZeneca.

Unlike conventional clinical healthcare—which relies on convoluted commercial health insurance reimbursements, HMO prior authorizations, and discounted Medicare/Medicaid fee schedules—the private clinical trial site industry operates on a 100% upfront, cash-grant sponsor model. Pharmaceutical companies and biotechnology sponsors contract directly with Site Management Organizations (SMOs) and dedicated clinical trial facilities, paying substantial per-patient study budgets ranging from $15,000 to over $45,000 per completed protocol. Out of this budget, participants receive modest stipends ($50 to $150 per visit on reloadable debit cards) for their time, travel, and blood draws, while the research facility captures the remaining spread to cover regulatory overhead, clinical research coordinator (CRC) salaries, laboratory equipment, and substantial operating profit.

This financial architecture has transformed clinical research into an extraordinarily lucrative asset class for private equity rollups:

• The Private Equity Platform Play: In October 2023, New York private investment firm VSS Capital Partners teamed with veteran clinical entrepreneur Dr. Ella Grach, M.D. (who previously founded Wake Research and scaled it into North America’s largest independent site network before selling to M3 Inc.) to launch Eximia Research Network. Eximia has built a multi-specialty clinical research platform targeting high-prevalence indications—major depression, migraines, COPD, and vaccines—with a rapid Southern California footprint anchored by Eximia Research-CA (La Mesa/San Diego), Leading Edge Research (Encino/San Fernando Valley), and active recruitment corridors partnering with Burbank clinical investigators such as Premiere Medical Center of Burbank at 201 S. Buena Vista St.
• The $500M Rollup Precedent: Eximia’s expansion mirrors the trajectory of Velocity Clinical Research, which in 2019 acquired Burbank’s pioneering Providence Clinical Research (founded in 2004 by Dr. Teresa S. Sligh, M.D. and Dr. Scott Sligh at 3808 W. Riverside Dr.). Two years later, London healthcare private equity giant GHO Capital acquired Velocity in an estimated $500 million transaction, consolidating hundreds of investigator sites into a global clinical trial engine.
• Specialized Independent Clinical Hubs: Alongside private equity networks, Burbank hosts premier niche research sites. At 847 N. Hollywood Way, Dr. Mitchell Nides, Ph.D. operates Los Angeles Clinical Trials (LACT), having served as Principal Investigator on more than 60 clinical trials for smoking cessation therapies, Chantix (varenicline), cytisinicline, and FDA Premarket Tobacco Applications (PMTA). On Magnolia Boulevard, Monica Torres directs Velvet Clinical Research (2211 W. Magnolia Blvd / 814 N. Hollywood Way), conducting Phase I–IV metabolic, vaccine, and pain management trials.
• The Commercial Testing & Diagnostic Duopoly: Flanking these clinical trial sites is a massive network of clinical diagnostic and pathology laboratories. Wall Street giants Laboratory Corporation of America Holdings (NYSE: LH) ($12.2B revenue) and Quest Diagnostics (NYSE: DGX) ($9.25B revenue) control key facilities across West Alameda Avenue and Buena Vista Street, joined by BioReference Laboratories (an OPKO Health company, NASDAQ: OPK, chaired by billionaire Dr. Phillip Frost) on Winona Avenue, and high-complexity regional CLIA testing laboratories including PIL Lab (Physicians ImmunoDiagnostic Laboratory) on Verdugo Drive and Alpha Clinical Laboratory on San Fernando Boulevard.

Corporate Governance: Ultimate Beneficial Ownership & Executive Leadership

In accordance with the investigative standards of Burbank Ledger, every corporate entity, commercial clinical facility, and diagnostic testing provider must be traced beyond local shell filings, professional corporations (PCs), and operating LLCs to identify ultimate beneficial owners, founders, CEOs, and private equity sponsors.

The Anatomy of Clinical Trial Site Economics: The $15,000–$45,000 Protocol Spread

To understand why private equity firms like VSS Capital Partners (Eximia) and GHO Capital (Velocity) are pouring hundreds of millions of dollars into clinical research site networks, one must examine the microeconomics of the clinical trial study contract.

When a pharmaceutical or biotechnology company designs a Phase II or Phase III clinical study for an investigational drug, it prepares a standardized investigator grant budget. This budget is negotiated between the sponsor (or its Contract Research Organization, such as IQVIA, Syneos Health, or PPD) and the trial site. Unlike the fee-for-service commercial insurance model—where physicians bill insurance companies and wait months for discounted payments subject to denials—clinical trial site grants are paid entirely in cash on milestone completion schedules:

For a specialized research site that enrolls 200 to 300 active study participants annually across 15 to 25 simultaneous protocols (such as Eximia’s multi-center network or Velocity’s North Hollywood/Burbank site), gross study revenues quickly reach $5 million to $12 million per facility. Because clinical site revenue is derived exclusively from corporate pharmaceutical R&D budgets—which are legally mandated by the FDA to complete Phase I safety, Phase II efficacy, and Phase III pivotal multi-center trials before a new drug application (NDA) can be approved—the cash flows are highly resilient and completely immune to government healthcare cuts, Medicare reimbursement caps, or commercial HMO denials.

Eximia Research Network: Private Equity Rollup & The Burbank Axis

The formation of Eximia Research Network represents the latest evolution in the corporate consolidation of clinical trial sites. In October 2023, New York private equity firm VSS Capital Partners announced a major growth capital investment to create Eximia as a dedicated clinical site platform.

To lead the platform, VSS recruited Dr. Ella Grach, M.D., one of the most recognized figures in the commercial trial industry. Dr. Grach originally founded Wake Research Associates in Raleigh, North Carolina, in 1984. Over three decades, she pioneered the centralized site management model, executing hundreds of clinical trials and acquiring independent investigator clinics across the United States. In 2018, Wake Research was acquired by Tokyo-listed healthcare conglomerate M3 Inc., where Dr. Grach served as President and CEO of M3 Wake Research, executing rapid add-on acquisitions before stepping down in late 2022.

Under Dr. Grach’s leadership, Eximia immediately deployed VSS’s capital to execute a multi-region rollup strategy:

• Sundance Clinical Research: Partnered in October 2023 to secure a massive Midwest clinical footprint in St. Louis, Missouri.
• Tidewater Clinical Research: Integrated in mid-2024 to expand capabilities in women’s health, endocrinology, and ophthalmology.
• The Southern California Network (Eximia Research-CA & Leading Edge): Operating formal network hubs through Eximia Research-CA, LLC (based in La Mesa/San Diego) and Leading Edge Research in Encino (serving the San Fernando Valley), Eximia has developed active clinical trial recruitment funnels targeting Burbank and adjacent Los Angeles communities.
• Burbank Clinical Trial Integration: In clinical trial registries (such as ClinicalTrials.gov protocols for major depressive disorder, COPD, and migraine treatments), Eximia’s local operations coordinate with community physician practices and medical centers in the Burbank/Toluca Lake area, including partnerships affiliated with Premiere Medical Center of Burbank (Med Partners, Inc.) at 201 S. Buena Vista St., Suite 325—directly across from Providence Saint Joseph Medical Center.

Eximia’s recruitment campaigns in the Burbank area prominently feature compensated clinical trials for high-prevalence chronic diseases:

1. Major Depressive Disorder (MDD): Testing novel fast-acting neuro-modulators and next-generation antidepressants, offering participants up to $1,200 in visit stipends, free psychiatric evaluations, and study medication.
2. Chronic Obstructive Pulmonary Disease (COPD): Recruiting current or former smokers in Burbank and the San Fernando Valley for next-generation inhaled biologics and bronchodilators, providing free pulmonary function testing (spirometry) and medical monitoring.
3. Migraine Prevention & Acute Treatment: Enrolling frequent migraine sufferers for targeted CGRP inhibitors and monoclonal antibody therapies.
4. Vaccine & Healthy Volunteer Studies: Conducting safety and immunogenicity studies for next-generation RSV, influenza, and combination mRNA vaccines.

Burbank’s Independent Clinical Trial Hubs: From Smoking Cessation to Phase I Inpatient Beds

While private equity-backed platforms like Eximia and Velocity dominate industry headlines, Burbank has long been an epicenter of specialized, clinician-led clinical trial research.

1. Los Angeles Clinical Trials (Dr. Mitchell Nides, Ph.D.) — 847 N. Hollywood Way

Operating out of Suite 103 in the two-story commercial office building at 847 N. Hollywood Way (AIN 2480-013-023), Los Angeles Clinical Trials (LACT) is one of the nation’s preeminent centers for tobacco dependence, smoking cessation, and respiratory product development.

Founded and presided over by Dr. Mitchell Nides, Ph.D., LACT has conducted research for over 25 years. Dr. Nides has served as Principal Investigator on more than 60 pivotal smoking cessation clinical trials, testing nearly every FDA-approved cessation pharmacotherapy on the market today—including nicotine replacement gums, transdermal patches, nasal sprays, oral inhalers, Zyban (bupropion), and Pfizer’s landmark smoking cessation drug Chantix (varenicline).

In recent years, Dr. Nides has been at the forefront of clinical trials evaluating cytisinicline (a plant-based alkaloid developed by Achieve Life Sciences) and assisting electronic cigarette manufacturers with the rigorous clinical testing required for FDA Premarket Tobacco Applications (PMTA). LACT’s clinical facility conducts pharmacokinetic (PK) blood-draw protocols, aerosol abuse-liability assessments, and cessation efficacy studies, drawing heavy participation from smokers and vapers throughout Burbank, Glendale, and North Hollywood.

2. Velvet Clinical Research (Monica Torres) — 2211 W. Magnolia Blvd & 814 N. Hollywood Way

Located in Suite 250 of the commercial medical building at 2213 W. Magnolia Blvd (AIN 2448-028-035) in the heart of the Magnolia Park commercial district, and operating an auxiliary clinical site at 814 N. Hollywood Way (AIN 2480-011-020), Velvet Clinical Research conducts Phase I through Phase IV multi-specialty clinical trials under the executive direction of Monica Torres.

Velvet Clinical Research specializes in multi-therapeutic recruitment across complex chronic indications, including Type II diabetes, non-alcoholic fatty liver disease (NASH/MASH), osteoarthritis pain management, dermatology, and preventative vaccines. The facility features dedicated phlebotomy stations, ECG testing bays, locked -20°C and -80°C investigational drug storage freezers, and private patient examination suites, serving as a vital bridge between San Fernando Valley patients and biopharmaceutical study sponsors.

3. Velocity Clinical Research (Formerly Providence Clinical Research) — 3808 W. Riverside Dr.

Before its acquisition by national site network Velocity Clinical Research (and subsequent $500M buyout by London PE sponsor GHO Capital), Providence Clinical Research was founded in Burbank in 2004 by Dr. Teresa S. Sligh, M.D. and Dr. Scott Sligh.

Operating out of Suite 200 at 3808 W. Riverside Dr. (AIN 2485-005-017) along the Riverside commercial corridor, the Slighs constructed a world-class investigative facility. Unlike standard outpatient clinics, the facility was engineered with a 30-bed inpatient Phase I early development research center, a specialized sleep laboratory for extended overnight pharmacokinetic monitoring, and a 3,000-square-foot outpatient testing suite. Dr. Teresa Sligh has served as Principal Investigator on hundreds of studies spanning metabolic disorders, cardiovascular disease, asthma, and rapid-response vaccine development. Velocity’s acquisition of the Burbank/North Hollywood operation provided GHO Capital with a high-capacity Phase I–IV flagship anchor in the Los Angeles metropolitan market.

The Commercial Testing Backbone: Wall Street Giants & Regional CLIA Reference Labs

Operating in tandem with clinical trial sites is Burbank’s commercial diagnostic and pathology testing infrastructure. Clinical trials generate thousands of biospecimens—blood serum, plasma, urine, and tissue biopsies—that require rapid processing, centrifugal separation, and high-complexity CLIA/CAP-certified diagnostic testing.

1. The Alameda Medical Corridor Duopoly: Labcorp & Quest Diagnostics

Across West Alameda Avenue, two publicly traded diagnostic monopolies control major testing facilities that serve both clinical trial protocols and local hospital systems:

• Labcorp (Laboratory Corporation of America Holdings, NYSE: LH): Located at 2701 W. Alameda Ave., Suite 203 (AIN 2484-021-016), Labcorp’s Burbank center operates as a regional clinical draw and specimen logistics hub. Under Chairman & CEO Adam H. Schechter, Labcorp generates over $12.16 billion in annual revenue, operating specialized clinical trial diagnostic arms (formerly Labcorp Drug Development / Covance) that perform central laboratory testing for Phase I–IV trials worldwide.
• Quest Diagnostics Inc. (NYSE: DGX): Located at 2601 W. Alameda Ave. (AIN 2484-021-018) and operating an outpatient clinical center inside Burbank Medical Plaza I at 201 S. Buena Vista St. (AIN 2484-019-019), Quest Diagnostics represents a $9.25 billion commercial testing empire directed by Chairman & CEO James E. Davis. Quest’s Burbank facilities handle high-volume routine and esoteric clinical diagnostic chemistry, immunoassay, and molecular testing.

2. BioReference Laboratories (OPKO Health, NASDAQ: OPK) — 3401 Winona Ave.

Situated in the light industrial corridor at 3401 Winona Ave., Unit 101 (AIN 2466-008-026), BioReference Laboratories operates a licensed commercial clinical reference laboratory holding CLIA Certificate of Accreditation. BioReference is the clinical diagnostic engine of OPKO Health, Inc. (NASDAQ: OPK), the diversified biopharmaceutical conglomerate founded and chaired by billionaire healthcare executive Dr. Phillip Frost, M.D.. While OPKO Health generates over $860 million in revenue, BioReference provides specialized oncology, urology, and women’s health reference testing for regional clinics and clinical trial sites.

3. Regional Independent CLIA Laboratories: PIL Lab & Alpha Clinical

Burbank also hosts specialized independent clinical testing laboratories:

• PIL Lab Inc. (Physicians ImmunoDiagnostic Laboratory): Located at 512 S. Verdugo Dr. (AIN 2451-021-053), PIL Lab operates a comprehensive, state-licensed and CLIA-certified medical laboratory providing clinical chemistry, hematology, microbiology, immunology, toxicology, and molecular biology testing.
• Alpha Clinical Laboratory: Located at 3021 N. San Fernando Blvd., Suite C (AIN 2466-023-037), Alpha Clinical specializes in high-complexity molecular pathology, infectious disease testing, and quantitative toxicology, supporting regional clinical trial programs and medical practices.

The Real Estate Cadastre: Mapping $118M in Burbank Medical Testing Parcels

By querying the official City of Burbank GIS Public Landbase Cadastre (FeatureServer/17) and cross-referencing secured property tax rolls from the Los Angeles County Office of the Assessor, we can map the exact parcel identifiers, underlying ownership entities, building footprints, assessed values, and statutory Proposition 13 base years for Burbank’s medical research and clinical testing facilities:

The cadastre audit reveals a combined assessed real estate roll of $118,102,247 across these 10 medical research and testing facilities. Furthermore, the data demonstrates the profound distortions created by statutory Proposition 13 base-year resets:

• The 2022 Reset on West Alameda: When 2701 W. Alameda Ave. (housing Labcorp) was acquired by Ocotillo LA 2701 LLC, its tax base reset to 2022 at $25.2 million ($483.74 per building sq. ft.), generating approximately $300,000 annually in local ad valorem property taxes.
• The Frozen 1997 Industrial Base on Winona: In stark contrast, 3401 Winona Ave. (housing BioReference Laboratories) remains anchored to a 1997 tax base of just $1.53 million ($126.24 per building sq. ft.)—an effective 3.8-to-1 assessment divide per square foot compared to the newly reassessed Alameda medical corridor.
• The Ground Lease Architecture of Burbank Medical Plaza I: At 201 S. Buena Vista St., the 73,453-square-foot medical office plaza housing Eximia’s research partner (Premiere Medical Center of Burbank) and Quest Diagnostics operates under an assessed valuation of $38.58 million. The title is structured as a master ground sublease (NHP PMB Burbank Medical Plaza I LLC) from the Sisters of Providence in California, reflecting the intimate physical and structural symbiosis between Burbank’s private clinical research economy and Providence Saint Joseph Medical Center.

Mandatory Financial Audit: SEC Form 10-K, Private Equity Portfolio & Site Economics

In accordance with the investigative requirements of Burbank Ledger, the table below documents the operating revenue, expense structures, profitability metrics, and tax provisions for the corporate platforms, clinical research site management networks, and commercial diagnostic testing providers operating within Burbank’s borders:

The financial audit reveals a striking economic contrast between high-volume commercial reference laboratories and specialized clinical research site networks:

• The Clinical Trial Margin Advantage: While Wall Street laboratory duopolists Labcorp and Quest Diagnostics operate at net profit margins of 3.5% and 9.2% respectively—weighed down by complex health insurance billing, Medicare PAMA fee schedule reductions, and bad debt reserves—clinical research site networks like Eximia, Velocity, and LACT capture operating margins of 22% to 28%. Because clinical trial sites are paid in guaranteed cash milestone tranches directly by pharmaceutical sponsors, they carry virtually zero bad debt and require no medical billing reconciliation staff.
• The Capital Efficiency of the SMO Model: For private equity sponsors like VSS Capital Partners, clinical site networks represent ideal platform rollups. A clinical trial site requires modest CapEx—standard commercial office leases, centrifuges, -80°C freezers, ECG machines, and examination tables—allowing 70% to 80% of EBITDA to convert directly into free cash flow. This free cash flow is then leveraged to fund bolt-on acquisitions of independent sites in complementary geographic markets.

Civic Accountability, FDA Compliance & The Shadow Healthcare Safety Net

The rapid expansion of commercial clinical trial networks in Burbank raises profound questions regarding municipal healthcare access, bioethical protections, and civic transparency.

1. Clinical Trials as Informal Safety Net Healthcare

In an era of rising deductibles, skyrocketing copays, and restrictive commercial HMO networks, commercial clinical trial sites have quietly become an informal healthcare safety net for uninsured and underinsured San Fernando Valley residents.

When an individual in Burbank enrolls in an Eximia Research depression trial or a Velvet Clinical Research diabetes study, they receive comprehensive diagnostic laboratory workups, physical examinations by board-certified physicians, investigational medications, and psychiatric or pulmonary monitoring at zero out-of-pocket cost. Furthermore, the financial stipends—ranging from $500 to $1,800 over the course of a 12-week study—provide essential financial support for working-class participants coping with Los Angeles County’s exorbitant cost of living.

However, bioethicists caution that financial compensation can inadvertently exert "undue inducement" on vulnerable, low-income patients, encouraging them to minimize physical side effects or conceal exclusion criteria (such as illicit substance use or concurrent medications) in order to qualify for study stipends.

2. FDA Form 1572 & Bioresearch Monitoring (BIMO) Oversight

Every physician serving as Principal Investigator in Burbank must execute FDA Form 1572 (Statement of Investigator), legally committing to personally conduct or supervise the investigation in compliance with 21 CFR Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards), and 312 (Investigational New Drug Application).

Inspections conducted under the FDA’s Bioresearch Monitoring (BIMO) program reveal that while Burbank’s established research sites maintain strong compliance records (predominantly classified as No Action Indicated / NAI or Voluntary Action Indicated / VAI for minor recordkeeping deviations), the nationwide private equity rollup trend introduces systemic risks. When independent clinics are acquired and centralized into nationwide platforms like Eximia or Velocity, local site coordinators often face aggressive enrollment quotas set by corporate headquarters. If patient recruitment speed is prioritized over meticulous protocol adherence, protocol deviations, incomplete adverse event reporting, and data integrity vulnerabilities can emerge.

3. Municipal Tax Contributions vs. Commercial Footprint

From a municipal finance perspective, clinical research sites and medical laboratories generate modest tax revenues for the City of Burbank:

• No Retail Sales Tax Yield: Unlike the commercial retail centers, auto dealerships, and restaurants along San Fernando Boulevard and Empire Center, clinical research sites do not sell physical consumer goods and generate zero municipal sales tax.
• Ad Valorem Property Taxes: With $118.1 million in assessed commercial real estate across 10 key parcels, these medical and lab facilities contribute approximately $1.4 million annually in property taxes, of which the City of Burbank’s General Fund receives roughly 17% ($238,000), with the remainder allocated to Los Angeles County, the Burbank Unified School District (BUSD), and regional flood/water districts.
• Business License Taxes: Under the Burbank Municipal Code, clinical research facilities and professional corporations pay gross receipts or flat-rate business license taxes, which remain capped at modest statutory rates compared to their multi-million-dollar biopharmaceutical grant revenues.

As biopharmaceutical R&D budgets continue to expand and private equity platforms like VSS Capital Partners’ Eximia Research Network aggressively consolidate Southern California’s clinical trial infrastructure, Burbank’s medical office corridors will remain a vital, highly profitable proving ground for the next generation of global therapeutics.